Onera Health, maker of a sleep apnea diagnosis patch that has Europe’s CE mark and is pending evaluation by the US Food & Drug Administration, recently closed €10.5M in Series B funding. which brought the total funding raised to date above the €24M mark.
Led by Innovation Industries in close collaboration with Invest-NL and with existing investors Jazz Pharmaceuticals, imec.xpand, BOM, and 15th Rock, the company intends to use the funds to execute clinical studies and further commercialize its sleep diagnostics and monitoring products in Europe and the United States.
“We’re going to leverage the funding to conduct progressively larger scale clinical studies, expand our partnerships in the [European Union] and US, and expedite product development to broaden our portfolio in sleep diagnostics and monitoring,” says Ruben de Francisco, founder, chief technology officer, and interim CEO of Onera, in a release. “This will facilitate the commercialization of our products and help the medical field provide the much-needed answers for millions who are affected by sleep disorders. We are excited to have such strong support from investors who share our vision.”
Harm de Vries, partner at Innovation Industries, says in a release, “We are delighted to lead this investment in Onera as the company is perfectly positioned to support the evolution of hospital-quality care to the home by its innovative sleep diagnostic products. With its world-class team, partners, and disruptive technology, we believe Onera is able to democratize gold-standard sleep medicine.”
Leo Holwerda, director capital of Invest-NL, says in a release, “Our investment in Onera is another good example of how we support promising Dutch start-ups and innovative companies to bring high-impact technologies and solutions to the market.”
Tom Vanhoutte, partner at imec.xpand, says in a release, “From the very beginning, we were convinced that Onera has the potential to revolutionize the remote monitoring industry. We look forward to seeing Onera’s continued success, enabled by this investment, in the commercialization of its products in Europe and the United States.”
Last month, Onera showcased its first-generation product at SLEEP 2021 and presented its latest research to experts.
Onera recently relocated its headquarters to the Brainport region in Eindhoven, the Netherlands, while maintaining commercial operations in the United States.